Bellicum Pharmaceuticals Inc(BLCM) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. It has collaboration and license agreements with Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

Current Price

$3.38

RSI

52.886

Beta:

1.746828

November 05, 2020
29.1M
-13.4M

23.005 %
97.232 %
55.222 %

$7,143,000
$1,120,000
$185,000
$388,000
$282,000
$1,780,523
537.768 %
505.405 %
-109.730 %
37.589 %
-531.391 %

$-112,477,000
$-98,036,000
$-91,842,000
$-68,922,000
$-48,850,000
$-83,964,789
-12.839 %
-6.318 %
-24.956 %
-29.123 %
71.883 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.